Comorbidity assessment in patients with a high probability of coronary artery disease with varying coronary calcium scores

Aim. To assess comorbidities in patients with varying coronary calcification who visited a general practitioner. Material and methods. The study included patients without a confirmed diagnosis of coronary artery disease (CAD) but with its risk factors. All patients underwent a pre-test assessment of CAD probability. The study included a total of 100 patients, in which an Agatston score was assessed using multislice computed tomography (MSCT) and the SmartScore software application. Patients without coronary artery calcification and with an Agatston index <11 were excluded. Of the 59 participants, three following groups were formed: group 1 — coronary calcium score 11- 100 (n=19), group 2 — 101-400 (n=20), group 3 — ≥401 U (n=20). Results. In the formed groups n=19/20/20, the following were established: mean age (M±m, years): 60,7±1,4; 63,3±1,3; 67,2±1,03, coronary calcification score (M±m, U): 44,8±4,8; 294,4±18,1; 715,8±25,9 and pre-test CAD probability (M±m, %): 16,3±1,3; 17,3±1,2; 21,2±1,8, respectively. There was following distribution of comorbidities in the groups (n/%): chronic obstructive pulmonary disease (COPD): 4/21,1; 3/15,0; 9/45,0; type 2 diabetes (T2D): 7/36,8; 4/20,0; 5/25,0; asthma: 3/15,8; 7/35,0; 3/15,0; no COPD/asthma/T2D: 5/26,3%; 6/30,0%; 3/15,0%, respectively. Conclusion. When conducting screening measures and assessing the pre-test CAD probability, COPD and asthma should be carefully identified, and, if present, CCS should be studied.